FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136135819> ?p ?o ?g. }

• W3136135819 endingPage "S639" @default.
• W3136135819 startingPage "S638" @default.
• W3136135819 abstract "In a phase II umbrella study (NCT03085069), camrelizumab (a potent anti–PD-1 monoclonal antibody) demonstrated promising efficacy and manageable safety profile as second-line treatment in advanced/metastatic NSCLC. Patients with higher PD-L1 expression derived greater benefit from camrelizumab. Here we present an updated OS, PFS, and PFS2 based on longer follow-up. Patients who had progressed during or following platinum-based doublet chemotherapy were enrolled and assigned to 4 cohorts according to PD-L1 tumor proportion score (TPS) to receive camrelizumab at 200 mg IV Q2W. Patients with EGFR or ALK alterations who had progressed on at least one approved tyrosine kinase inhibitor and with PD-L1 TPS ≥50% were eligible. PFS2 was defined as time from first dose of camrelizumab to objective tumor progression on next-line treatment or death from any cause, whichever occurred first. From May 24, 2017 to Aug 1, 2018, 146 patients were enrolled. As of data cutoff on Jan 31, 2020, the median follow-up was 22.9 months (95% CI 21.7–24.2). Median OS and PFS was 14.8 months (95% CI 10.3–18.8) and 3.2 months (95% CI 2.0–3.4), respectively. Third-line therapy and beyond was received by 65 (44.5%) patients. PFS2 was 10.0 months (95% CI 8.2–12.4). Subgroup analysis showed that patients with positive PD-L1 TPS commonly had longer PFS and PFS2 (Table 1). No new safety signal with camrelizumab was identified.Table 1Survival of camrelizumab in PD-L1 TPS subgroupsPopulationNo. of patientsOS (months), median (95% CI)PFS (months), median (95% CI)PFS2 (months), median (95% CI)PD-L1 TPS <1%749.2 (6.5–15.4)2.1 (1.9–3.2)7.5 (5.7–8.9)PD-L1 TPS ≥1%7223.3 (13.2–NR)3.8 (2.0–7.2)16.6 (10.2–19.8)PD-L1 TPS 1–49%42NR (14.8–NR)3.4 (1.8–6.0)16.9 (10.2–20.4)PD-L1 TPS ≥50% (without EGFR alterations)2523.3 (9.0–NR)7.6 (2.0–16.8)18.7 (9.0–26.8)PD-L1 TPS ≥50% (with EGFR alterations)510.3 (1.2–NR)1.7 (1.2–NR)9.8 (1.2–16.6)ITT14614.8 (10.3–18.8)3.2 (2.0–3.4)10.0 (8.2–12.4)NR, not reached. Open table in a new tab NR, not reached. The updated results demonstrated improved survival compared with historical data of the second-line chemotherapy. Patients with positive PD-L1 expression derived greater benefit from camrelizumab. These data supported the long-term outcome of camrelizumab as the second-line therapy in advanced/metastatic NSCLC." @default.
• W3136135819 created "2021-03-29" @default.
• W3136135819 creator A5006389158 @default.
• W3136135819 creator A5015980641 @default.
• W3136135819 creator A5016388128 @default.
• W3136135819 creator A5028266663 @default.
• W3136135819 creator A5028631107 @default.
• W3136135819 creator A5029909456 @default.
• W3136135819 creator A5031729031 @default.
• W3136135819 creator A5038306289 @default.
• W3136135819 creator A5041181413 @default.
• W3136135819 creator A5041465434 @default.
• W3136135819 creator A5044546691 @default.
• W3136135819 creator A5045553246 @default.
• W3136135819 creator A5052211998 @default.
• W3136135819 creator A5057769470 @default.
• W3136135819 creator A5061229595 @default.
• W3136135819 creator A5068044246 @default.
• W3136135819 creator A5071004395 @default.
• W3136135819 creator A5074092905 @default.
• W3136135819 creator A5084685237 @default.
• W3136135819 date "2021-03-01" @default.
• W3136135819 modified "2023-10-16" @default.
• W3136135819 title "P78.03 Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC" @default.
• W3136135819 doi "https://doi.org/10.1016/j.jtho.2021.01.1166" @default.
• W3136135819 hasPublicationYear "2021" @default.
• W3136135819 type Work @default.
• W3136135819 sameAs 3136135819 @default.
• W3136135819 citedByCount "0" @default.
• W3136135819 crossrefType "journal-article" @default.
• W3136135819 hasAuthorship W3136135819A5006389158 @default.
• W3136135819 hasAuthorship W3136135819A5015980641 @default.
• W3136135819 hasAuthorship W3136135819A5016388128 @default.
• W3136135819 hasAuthorship W3136135819A5028266663 @default.
• W3136135819 hasAuthorship W3136135819A5028631107 @default.
• W3136135819 hasAuthorship W3136135819A5029909456 @default.
• W3136135819 hasAuthorship W3136135819A5031729031 @default.
• W3136135819 hasAuthorship W3136135819A5038306289 @default.
• W3136135819 hasAuthorship W3136135819A5041181413 @default.
• W3136135819 hasAuthorship W3136135819A5041465434 @default.
• W3136135819 hasAuthorship W3136135819A5044546691 @default.
• W3136135819 hasAuthorship W3136135819A5045553246 @default.
• W3136135819 hasAuthorship W3136135819A5052211998 @default.
• W3136135819 hasAuthorship W3136135819A5057769470 @default.
• W3136135819 hasAuthorship W3136135819A5061229595 @default.
• W3136135819 hasAuthorship W3136135819A5068044246 @default.
• W3136135819 hasAuthorship W3136135819A5071004395 @default.
• W3136135819 hasAuthorship W3136135819A5074092905 @default.
• W3136135819 hasAuthorship W3136135819A5084685237 @default.
• W3136135819 hasBestOaLocation W31361358191 @default.
• W3136135819 hasConcept C121608353 @default.
• W3136135819 hasConcept C126322002 @default.
• W3136135819 hasConcept C143998085 @default.
• W3136135819 hasConcept C2776694085 @default.
• W3136135819 hasConcept C2777701055 @default.
• W3136135819 hasConcept C2780739268 @default.
• W3136135819 hasConcept C71924100 @default.
• W3136135819 hasConceptScore W3136135819C121608353 @default.
• W3136135819 hasConceptScore W3136135819C126322002 @default.
• W3136135819 hasConceptScore W3136135819C143998085 @default.
• W3136135819 hasConceptScore W3136135819C2776694085 @default.
• W3136135819 hasConceptScore W3136135819C2777701055 @default.
• W3136135819 hasConceptScore W3136135819C2780739268 @default.
• W3136135819 hasConceptScore W3136135819C71924100 @default.
• W3136135819 hasIssue "3" @default.
• W3136135819 hasLocation W31361358191 @default.
• W3136135819 hasOpenAccess W3136135819 @default.
• W3136135819 hasPrimaryLocation W31361358191 @default.
• W3136135819 hasRelatedWork W2552554696 @default.
• W3136135819 hasRelatedWork W2948610106 @default.
• W3136135819 hasRelatedWork W2994922817 @default.
• W3136135819 hasRelatedWork W3136141307 @default.
• W3136135819 hasRelatedWork W3137670083 @default.
• W3136135819 hasRelatedWork W4206639819 @default.
• W3136135819 hasRelatedWork W4211098472 @default.
• W3136135819 hasRelatedWork W4290617554 @default.
• W3136135819 hasRelatedWork W4322718939 @default.
• W3136135819 hasRelatedWork W4362706485 @default.
• W3136135819 hasVolume "16" @default.
• W3136135819 isParatext "false" @default.
• W3136135819 isRetracted "false" @default.
• W3136135819 magId "3136135819" @default.
• W3136135819 workType "article" @default.